表紙
市場調査レポート

Zeria Pharmaceutical Co Ltd:製品パイプライン分析

Zeria Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224668
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
Zeria Pharmaceutical Co Ltd:製品パイプライン分析 Zeria Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015
出版日: 2015年09月30日 ページ情報: 英文 38 Pages
概要

Zeria Pharmaceutical Co Ltd は、医薬品、動物用医薬品、非製薬製品、農薬、工業用化学物質、試薬の製造および輸出入を行っている製薬会社です。同社はまた、化粧品、アルコール飲料、食品添加物、健康食品、家畜の飼料、衛生用品、医療機器、健康器具、衛生施設、衛生器具、炭酸飲料、美容器具、計測器、分析機器などを製造販売しています。

当レポートでは、Zeria Pharmaceutical Co Ltdにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Zeria Pharmaceutical Co Ltdの基本情報

Zeria Pharmaceutical Co Ltdの概要

  • 主要情報
  • 企業情報

Zeria Pharmaceutical Co Ltd :R&Dの概要

  • 主な治療範囲

Zeria Pharmaceutical Co Ltd :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Zeria Pharmaceutical Co Ltd :パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ

Zeria Pharmaceutical Co Ltd :薬剤プロファイル

  • acotiamide hydrochloride
  • mycobacterium tuberculosis ext
  • polaprezinc
  • ZOSA-0
  • ZOY-60
  • Z-360
  • E-3710
  • ferric carboxymaltose

Zeria Pharmaceutical Co Ltd :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Zeria Pharmaceutical Co Ltd :最近のパイプライン動向

Zeria Pharmaceutical Co Ltd :休止中のプロジェクト

Zeria Pharmaceutical Co Ltd :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • acotiamide hydrochloride

Zeria Pharmaceutical Co Ltd :本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07601CDB

Summary

Global Markets Direct's, 'Zeria Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Zeria Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zeria Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Zeria Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Zeria Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Zeria Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Zeria Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Zeria Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Zeria Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Zeria Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zeria Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Zeria Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Zeria Pharmaceutical Co., Ltd. Snapshot
    • Zeria Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Zeria Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Zeria Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Zeria Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Zeria Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Zeria Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • Zeria Pharmaceutical Co., Ltd. - Drug Profiles
    • acotiamide hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polaprezinc
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Z-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZOSA-0
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • E-3710
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Z-360
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ferric carboxymaltose
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Zeria Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Zeria Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Zeria Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Zeria Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Zeria Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Zeria Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • Zeria Pharmaceutical Co., Ltd. - Dormant Projects
  • Zeria Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • acotiamide hydrochloride
  • Zeria Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zeria Pharmaceutical Co., Ltd., Key Information
  • Zeria Pharmaceutical Co., Ltd., Key Facts
  • Zeria Pharmaceutical Co., Ltd. - Pipeline by Indication, 2015
  • Zeria Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Zeria Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Zeria Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
  • Zeria Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Zeria Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • Zeria Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Zeria Pharmaceutical Co., Ltd. - Phase III, 2015
  • Zeria Pharmaceutical Co., Ltd. - Phase II, 2015
  • Zeria Pharmaceutical Co., Ltd. - Phase I, 2015
  • Zeria Pharmaceutical Co., Ltd. - Pipeline by Target, 2015
  • Zeria Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2015
  • Zeria Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2015
  • Zeria Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Zeria Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2015
  • Zeria Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2015
  • Zeria Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2015
  • Zeria Pharmaceutical Co., Ltd., Other Locations
  • Zeria Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Zeria Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Zeria Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Zeria Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Zeria Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
  • Zeria Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • Zeria Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Zeria Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Zeria Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Zeria Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top